Mortality benefit of isoniazid preventive therapy in HIV-positive persons: A simulation study

Marcus A. Bachhuber; R. Gross

Mortality benefit of isoniazid preventive therapy in HIV-positive persons: A simulation study

Marcus A. Bachhuber, R. Gross

Research output: Contribution to journal › Article › peer-review

Abstract

A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

Original language	English (US)
Pages (from-to)	1038-1040
Number of pages	3
Journal	International Journal of Tuberculosis and Lung Disease
Volume	13
Issue number	8
State	Published - Aug 2009
Externally published	Yes

Keywords

HIV
Isoniazid
Mortality
Tuberculosis

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{5e150149bc644f4da5dab7de13238061,

title = "Mortality benefit of isoniazid preventive therapy in HIV-positive persons: A simulation study",

abstract = "A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).",

keywords = "HIV, Isoniazid, Mortality, Tuberculosis",

author = "Bachhuber, {Marcus A.} and R. Gross",

year = "2009",

month = aug,

language = "English (US)",

volume = "13",

pages = "1038--1040",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union against Tubercul. and Lung Dis.",

number = "8",

}

TY - JOUR

T1 - Mortality benefit of isoniazid preventive therapy in HIV-positive persons

T2 - A simulation study

AU - Bachhuber, Marcus A.

AU - Gross, R.

PY - 2009/8

Y1 - 2009/8

N2 - A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

AB - A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

KW - HIV

KW - Isoniazid

KW - Mortality

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=69149110279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149110279&partnerID=8YFLogxK

M3 - Article

C2 - 19723386

AN - SCOPUS:69149110279

SN - 1027-3719

VL - 13

SP - 1038

EP - 1040

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 8

ER -

Mortality benefit of isoniazid preventive therapy in HIV-positive persons: A simulation study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this